患者偏好与价值框架一致吗?乳腺癌患者的离散选择实验。

IF 1.9 Q3 HEALTH CARE SCIENCES & SERVICES MDM Policy and Practice Pub Date : 2020-06-15 eCollection Date: 2020-01-01 DOI:10.1177/2381468320928012
Ilene L Hollin, Juan Marcos González, Lisabeth Buelt, Michael Ciarametaro, Robert W Dubois
{"title":"患者偏好与价值框架一致吗?乳腺癌患者的离散选择实验。","authors":"Ilene L Hollin,&nbsp;Juan Marcos González,&nbsp;Lisabeth Buelt,&nbsp;Michael Ciarametaro,&nbsp;Robert W Dubois","doi":"10.1177/2381468320928012","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose.</b> Assess patient preferences for aspects of breast cancer treatments to evaluate and inform the usual assumptions in scoring rubrics for value frameworks. <b>Methods.</b> A discrete-choice experiment (DCE) was designed and implemented to collect quantitative evidence on preferences from 100 adult female patients with a self-reported physician diagnosis of stage 3 or stage 4 breast cancer. Respondents were asked to evaluate some of the treatment aspects currently considered in value frameworks. Respondents' choices were analyzed using logit-based regression models that produced preference weights for each treatment aspect considered. Aggregate- and individual-level preferences were used to assess the relative importance of treatment aspects and their variability across respondents. <b>Results.</b> As expected, better clinical outcomes were associated with higher preference weights. While life extensions with treatment were considered to be most important, respondents assigned great value to out-of-pocket cost of treatment, treatment route of administration, and the availability of reliable tests to help gauge treatment efficacy. Two respondent classes were identified in the sample. Differences in class-specific preferences were primarily associated with route of administration, out-of-pocket treatment cost, and the availability of a test to gauge treatment efficacy. Only patient cancer stage was found to be correlated with class assignment (<i>P</i> = 0.035). Given the distribution of individual-level preference estimates, preference for survival benefits are unlikely to be adequately described with two sets of preference weights. <b>Conclusions.</b> Although value frameworks are an important step in the systematic evaluation of medications in the context of a complex treatment landscape, the frameworks are still largely driven by expert judgment. Our results illustrate issues with this approach as patient preferences can be heterogeneous and different from the scoring weights currently provided by the frameworks.</p>","PeriodicalId":36567,"journal":{"name":"MDM Policy and Practice","volume":"5 1","pages":"2381468320928012"},"PeriodicalIF":1.9000,"publicationDate":"2020-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2381468320928012","citationCount":"4","resultStr":"{\"title\":\"Do Patient Preferences Align With Value Frameworks? A Discrete-Choice Experiment of Patients With Breast Cancer.\",\"authors\":\"Ilene L Hollin,&nbsp;Juan Marcos González,&nbsp;Lisabeth Buelt,&nbsp;Michael Ciarametaro,&nbsp;Robert W Dubois\",\"doi\":\"10.1177/2381468320928012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Purpose.</b> Assess patient preferences for aspects of breast cancer treatments to evaluate and inform the usual assumptions in scoring rubrics for value frameworks. <b>Methods.</b> A discrete-choice experiment (DCE) was designed and implemented to collect quantitative evidence on preferences from 100 adult female patients with a self-reported physician diagnosis of stage 3 or stage 4 breast cancer. Respondents were asked to evaluate some of the treatment aspects currently considered in value frameworks. Respondents' choices were analyzed using logit-based regression models that produced preference weights for each treatment aspect considered. Aggregate- and individual-level preferences were used to assess the relative importance of treatment aspects and their variability across respondents. <b>Results.</b> As expected, better clinical outcomes were associated with higher preference weights. While life extensions with treatment were considered to be most important, respondents assigned great value to out-of-pocket cost of treatment, treatment route of administration, and the availability of reliable tests to help gauge treatment efficacy. Two respondent classes were identified in the sample. Differences in class-specific preferences were primarily associated with route of administration, out-of-pocket treatment cost, and the availability of a test to gauge treatment efficacy. Only patient cancer stage was found to be correlated with class assignment (<i>P</i> = 0.035). Given the distribution of individual-level preference estimates, preference for survival benefits are unlikely to be adequately described with two sets of preference weights. <b>Conclusions.</b> Although value frameworks are an important step in the systematic evaluation of medications in the context of a complex treatment landscape, the frameworks are still largely driven by expert judgment. Our results illustrate issues with this approach as patient preferences can be heterogeneous and different from the scoring weights currently provided by the frameworks.</p>\",\"PeriodicalId\":36567,\"journal\":{\"name\":\"MDM Policy and Practice\",\"volume\":\"5 1\",\"pages\":\"2381468320928012\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2020-06-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/2381468320928012\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MDM Policy and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/2381468320928012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MDM Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2381468320928012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 4

摘要

目的。评估患者对乳腺癌治疗方面的偏好,以评估和告知价值框架评分标准中的通常假设。方法。设计并实施了一项离散选择实验(DCE),以收集100名自我报告的医生诊断为3期或4期乳腺癌的成年女性患者的偏好定量证据。受访者被要求评估目前在价值框架中考虑的一些治疗方面。使用基于逻辑的回归模型对受访者的选择进行分析,该模型为所考虑的每个治疗方面产生偏好权重。总体和个人水平的偏好被用来评估治疗方面的相对重要性及其在应答者之间的可变性。结果。正如预期的那样,更好的临床结果与更高的偏好权重相关。虽然通过治疗延长生命被认为是最重要的,但答复者认为,自付治疗费用、给药治疗途径以及帮助衡量治疗效果的可靠测试的可得性非常重要。在样本中确定了两个应答者类别。班级特定偏好的差异主要与给药途径、自费治疗费用和衡量治疗效果的测试的可用性有关。只有患者的癌症分期与分类分配相关(P = 0.035)。考虑到个人偏好估计的分布,对生存利益的偏好不太可能用两组偏好权重来充分描述。结论。尽管在复杂的治疗环境中,价值框架是对药物进行系统评估的重要一步,但这些框架在很大程度上仍然是由专家判断驱动的。我们的结果说明了这种方法的问题,因为患者的偏好可能是异质的,并且与目前框架提供的评分权重不同。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Do Patient Preferences Align With Value Frameworks? A Discrete-Choice Experiment of Patients With Breast Cancer.

Purpose. Assess patient preferences for aspects of breast cancer treatments to evaluate and inform the usual assumptions in scoring rubrics for value frameworks. Methods. A discrete-choice experiment (DCE) was designed and implemented to collect quantitative evidence on preferences from 100 adult female patients with a self-reported physician diagnosis of stage 3 or stage 4 breast cancer. Respondents were asked to evaluate some of the treatment aspects currently considered in value frameworks. Respondents' choices were analyzed using logit-based regression models that produced preference weights for each treatment aspect considered. Aggregate- and individual-level preferences were used to assess the relative importance of treatment aspects and their variability across respondents. Results. As expected, better clinical outcomes were associated with higher preference weights. While life extensions with treatment were considered to be most important, respondents assigned great value to out-of-pocket cost of treatment, treatment route of administration, and the availability of reliable tests to help gauge treatment efficacy. Two respondent classes were identified in the sample. Differences in class-specific preferences were primarily associated with route of administration, out-of-pocket treatment cost, and the availability of a test to gauge treatment efficacy. Only patient cancer stage was found to be correlated with class assignment (P = 0.035). Given the distribution of individual-level preference estimates, preference for survival benefits are unlikely to be adequately described with two sets of preference weights. Conclusions. Although value frameworks are an important step in the systematic evaluation of medications in the context of a complex treatment landscape, the frameworks are still largely driven by expert judgment. Our results illustrate issues with this approach as patient preferences can be heterogeneous and different from the scoring weights currently provided by the frameworks.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
MDM Policy and Practice
MDM Policy and Practice Medicine-Health Policy
CiteScore
2.50
自引率
0.00%
发文量
28
审稿时长
15 weeks
期刊最新文献
Prioritizing Patients from the Most Deprived Areas on Elective Waiting Lists in the NHS in England: Estimating the Health and Health Inequality Impact. Optimizing Masks and Random Screening Test Usage within K-12 Schools. Associations of Concordant and Shared Lung Cancer Screening Decision Making with Decisional Conflict: A Multi-Institution Cross-Sectional Analysis. Implications of Diminishing Lifespan Marginal Utility for Valuing Equity in Cost-Effectiveness Analysis. Evaluation of the Soda Tax on Obesity and Diabetes in California: A Cost-Effectiveness Analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1